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Abstract
Objective—For decades it has been known that the HLA–DRB1 shared epitope (SE) alleles are 
associated with an increased risk of development and progression of rheumatoid arthritis (RA). 
Recently, the following variations in the peptide-binding grooves of HLA molecules that 
predispose to RA development have been identified: Val and Leu at HLA–DRB1 position 11, Asp 
at HLA–B position 9, and Phe at HLA–DPB1 position 9. This study was undertaken to investigate 
whether these variants are also associated with radiographic progression in RA, independent of SE 
and anti–citrullinated protein antibody (ACPA) status.
Methods—A total of 4,911 radiograph sets from 1,878 RA patients included in the Leiden Early 
Arthritis Clinic (The Netherlands), Umeå (Sweden), Hospital Clinico San Carlos–Rheumatoid 
Arthritis (Spain), and National Data Bank for Rheumatic Diseases (US) cohorts were studied. 
HLA was imputed using single-nucleotide polymorphism data from an Immunochip, and the 
amino acids listed above were tested in relation to radiographic progression per cohort using an 
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additive model. Results from the 4 cohorts were combined in inverse-variance weighted meta-
analyses using a fixed-effects model. Analyses were conditioned on SE and ACPA status.
Results—Val and Leu at HLA–DRB1 position 11 were associated with more radiographic 
progression (meta-analysis P = 5.11 × 10−7); this effect was independent of SE status (meta-
analysis P = 0.022) but not independent of ACPA status. Phe at HLA–DPB1 position 9 was 
associated with more severe radiographic progression (meta-analysis P = 0.024), though not 
independent of SE status. Asp at HLA–B position 9 was not associated with radiographic 
progression.
Conclusion—Val and Leu at HLA–DRB1 position 11 conferred a risk of a higher rate of 
radiographic progression independent of SE status but not independent of ACPA status. These 
findings support the relevance of these amino acids at position 11.
The development and course of rheumatoid arthritis (RA) are in part determined by genetic 
factors. Although the genetic risk factors underlying RA development and progression of 
joint destruction are largely nonoverlapping (1), the genetic variants encoding the so-called 
HLA–DRB1 shared epitope (SE) alleles are associated with both the risk of RA 
development and the severity of the disease course (2–4).
The association of HLA class II with RA has been known for decades. The association 
between HLA–DR and RA was first reported in 1976 (5). Subsequent identification of risk 
HLA–DRB1 alleles that all shared a similar amino acid sequence at positions 70–74 in the 
peptide-binding groove of the HLA–DRB1 molecule led to the formulation of the SE 
hypothesis (6). This hypothesis postulates that the SE motif itself may be directly involved 
in the pathogenesis of RA by allowing the presentation of an arthritogenic peptide to T cells. 
Thus far, these peptides have not been identified. With the identification of anti–citrullinated 
protein antibodies (ACPAs) in the late 1990s, it became clear that SE alleles mainly 
predispose to ACPA-positive RA (3,7). The relevance of HLA–DRB1 for ACPA-negative 
RA was set by the identification of HLA–DRB1*03 (part of the conserved ancestral A1-B8-
DRB1*03 haplotype) as a risk factor for ACPA-negative RA (8,9).
Recently, a further refinement of the association between HLA and RA was proposed by 
Raychaudhuri et al (10). Using a case–control design with 5,018 ACPA-positive RA patients 
and 14,974 controls, the class I and class II HLA regions were explored. The strongest 
association was reported for HLA–DRB1 positions 11 and 13 (which are in high linkage 
disequilibrium). The amino acids Val and Leu at position 11 conferred a high risk, and Ser 
was protective. These associations were independent of the SE status. Furthermore, 
performing further conditional analyses, independent associations were observed for 
variants in HLA–B position 9 (Asp predisposed to RA) and HLA–DPB1 position 9 (Phe 
predisposed to RA). In a subsequent study using a similar approach, the authors also 
investigated 2,406 ACPA-negative RA patients and 13,930 controls (11) and observed that 
Leu and Ser at HLA–DRB1 position 11 and Asp in HLA–B position 9 were associated with 
an increased risk of ACPA-negative RA.
These risk positions are located in the peptide-binding grooves of the HLA molecules. 
Studies of MHC class I and class II in mice have shown that a difference of only one or a 
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few amino acids at such a crucial place may result in the presentation of totally different 
peptides (12,13). Therefore, the finding that additional amino acids located in the antigen-
presenting binding grooves associate with RA development is relevant and hypothetically 
may fuel further studies to detect arthritogenic peptides involved in RA susceptibility (10).
Because the HLA–DRB1 SE alleles are among the strongest genetic factors for a 
progressive disease course, the recent findings of Raychaudhuri et al prompted us to 
determine the relevance of the newly identified risk factors for the severity of the course of 
RA, measured using radiographic joint damage progression. More specifically, first, we 
aimed to investigate whether Val, Leu, and Ser at HLA–DRB1 position 11, Asp at HLA–B 
position 9, and Phe at HLA–DPB1 position 9 are associated with radiographic progression 
in the total RA population and, if so, whether these effects are independent of the well-
known SE effect (HLA–DRB1 positions 70–74). Second, since the SE alleles predispose to 
ACPAs and the SE alleles are not associated with radiographic progression independent of 
ACPAs (7,14), we aimed to analyze whether the newly identified associations are 
independent of ACPAs. Third, we aimed to evaluate whether Leu and Ser at HLA–DRB1 
position 11 and Asp at HLA–B position 9, identified as risk factors for ACPA-negative RA, 
are associated with joint damage progression in ACPA-negative RA. To this end, a total of 
4,911 sets of radiographs of 1,878 patients with RA in 4 different cohorts were studied.
PATIENTS AND METHODS
Patients
Patients were included from the following 4 cohorts: the Leiden Early Arthritis Clinic 
(EAC), the Umeå cohort, the Hospital Clinico San Carlos–Rheumatoid Arthritis Cohort 
(HCSC-RAC), and the National Data Bank for Rheumatic Diseases (NDB). In all cohorts, 
RA was defined according to the American College of Rheumatology 1987 criteria (15). 
The characteristics of the patients in each cohort are presented in Supplementary Table 1, 
available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/
10.1002/art.39018/abstract. Informed consent was obtained from all patients, and approval 
was obtained from the local ethics committee of each study.
Leiden EAC—This cohort consisted of 594 Dutch patients with early RA who were 
enrolled between 1993 and 2006 (16). The mean ± SD age at diagnosis was 57.0 ± 15.6 
years, 67.0% of the patients were women, and 52.8% were ACPA positive (as determined 
by anti–cyclic citrullinated peptide 2 [anti–CCP-2] antibody test). Radiographs of the hands 
and feet were obtained at baseline and during yearly followup visits. In total 3,121 sets of 
radiographs obtained over 7 years of followup were chronologically scored by 1 experienced 
reader, who was blinded with regard to any clinical or genetic data, using the Sharp/van der 
Heijde score (SHS) (within reader intraclass correlation coefficient [ICC] 0.91). Initial 
treatment strategies changed over time. Patients enrolled in 1993–1995 were initially treated 
with nonsteroidal antiinflammatory drugs (NSAIDs), patients enrolled in 1996–1998 were 
initially treated with hydroxychloroquine or sulfasalazine, and patients enrolled in 1999–
2006 were initially treated with methotrexate.
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Umeå cohort—This Swedish cohort comprised 365 patients with early RA enrolled 
between 1995 and 2010. The mean ± SD age at diagnosis was 54.3 ± 14.5 years, 69.6% of 
the patients were women, and 71.8% were ACPA positive (as determined by anti–CCP-2 
antibody test). At baseline and after 2 years, a total of 687 radiographs of the hands and feet 
were obtained and scored using the Larsen score by 2 trained readers as previously 
described (17). Treatment strategies differed between 1995–2000, 2000–2005, and 2006–
2010, resulting in less severe radiographic progression in the subsequent treatment periods.
HCSC-RAC—This Spanish data set involved 380 patients with early RA, diagnosed 
between 1976 and 2011 (18). The mean ± SD age at diagnosis was 53.8 ± 14.2 years, 76.3% 
of the patients were women, and 48.6% were ACPA positive (as determined by anti–CCP-2 
antibody test). During the first 10 years after disease onset, 564 radiographs of the hands 
were obtained and scored with known time-order using the SHS (ICC 0.99). Initial treatment 
strategies differed for different inclusion periods. Prior to 1990, patients were initially 
treated with NSAIDs, from 1990 to 1999 patients received initial monotherapy with 
conventional disease-modifying antirheumatic drugs, from 2000 to 2004 patients received 
initial monotherapy regularly and combination therapy rarely, from 2005 to 2009 patients 
received initial combination therapy regularly as well as biologic agents, and from 2010 to 
2011 patients received tailored treatment.
NDB—This data set included 539 patients from the US and Canada who were diagnosed 
between 1980 and 1999 (19). The mean ± SD age at diagnosis was 48.6 ± 12.6, 78.5% of the 
patients were women, and 79.6% were ACPA positive (as determined by anti–CCP-2 
antibody test). One set of hand radiographs was available per patient after a mean disease 
duration of 10.1 years (range 1–20 years) and scored according to the SHS (ICC 0.98). No 
treatment effects were observed for different periods of diagnosis since all patients 
developed RA in eras when early, tailored treatment and the use of biologic agents were 
uncommon.
Genotyping
For all cohorts, we used SNP2HLA to impute classic alleles and corresponding amino acid 
polymorphisms for HLA class I loci (HLA–A, –B, and –C) and class II loci (HLA–DPA1, –
DPB1, –DQA1, –DQB1, and –DRB1) (20). We obtained patient genotypes using an 
Illumina Immunochip platform (1,21) and used data collected by the Type 1 Diabetes 
Genetics Consortium as a reference (22). The HLA imputation has been described in detail 
previously (10,11,20). For the present study, the classic HLA–DRB1 alleles and the amino 
acids at HLA–DRB1 position 11, HLA–B position 9, and HLA–DPB1 position 9 were 
extracted.
Analyses of the associations between variants and radiographic progression
First, the SE alleles, defined based on HLA–DRB1 positions 70–74 according to the SE 
hypothesis (6) (DRB1*0101, *0102, *0104, *0401, *0404, *0405, *0408, *0413, *0416, 
*1001, and *1402), were tested in relation to radiographic progression. Subsequently, the 
amino acids that were shown to confer risk to develop RA in the study by Raychaudhuri et 
al (10) (Val and Leu at HLA–DRB1 position 11, Asp at HLA–B position 9, and Phe at 
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HLA–DPB1 position 9) were studied in relation to radiographic progression. Analyses were 
done per cohort using an additive model (0, 1, or 2 risk amino acids). Since Val and Leu at 
position 11 both conferred increased risk, these were combined (i.e., radiographic 
progression in the presence of 0, 1, or 2 Val and/or Leu was studied). Because the SE alleles 
and Val or Leu on position 11 are often present together, conditional analyses were 
performed allowing us to investigate whether Val and Leu were associated with 
radiographic progression independent of the known association between HLA–DRB1 SE 
status and radiographic progression. Furthermore, for the SE alleles it is known that the 
alleles are not associated with radiographic progression independent of ACPAs; in other 
words, the SE alleles are not associated with radiographic progression as such but this effect 
is mediated by ACPAs (7,14). To determine whether the same is valid for the newly 
identified risk factors, analyses were subsequently adjusted for ACPA status.
Previously, the amino acid Ser at HLA–DRB1 position 11 was found to protect against RA 
development (10). In this study, the association of Ser (0, 1, or 2 amino acids) with 
radiographic progression was analyzed.
The above-mentioned analyses of Val and Leu and of Ser at HLA–DRB1 position 11 do not 
take into account the polymorphic nature of HLA–DRB1 in which different amino acids 
encoded by the same position may have a predisposing or protective effect. It is crucial to 
ascertain that the predisposing effect identified is not actually due to the absence of a 
protective effect and vice versa. Stratification is the most thorough method to differentiate 
between these effects and has been used before to distinguish true effects from the effect of 
the absence of other alleles (2,23,24). Therefore, patients were stratified into one of the 
following 6 groups: susceptible/susceptible (S/S), susceptible/neutral (S/N), susceptible/
protective (S/P), neutral/neutral (N/N), neutral/protective (N/P), and protective/protective 
(P/P). Val and Leu at HLA–DRB1 position 11 were the susceptibility amino acids, Ser at 
this position was the protective amino acid, and Asp, Pro, and Gly were the neutral amino 
acids. Then the groups of S/S, S/N, and N/N were compared to determine whether the effect 
of Val and Leu was truly predisposing and not the result of the concomitant absence of Ser. 
Similarly, the groups of P/P, P/N, and N/N were compared to determine whether the effect 
of Ser was truly protective and not the result of the concomitant absence of the susceptibility 
amino acids Val and Leu.
Finally, we evaluated whether the variants that were reported to predispose to ACPA-
negative RA (11) (Leu and Ser at HLA–DRB1 position 11 and Asp at HLA–B position 9) 
were associated with radiographic progression in ACPA-negative RA.
Statistical analysis
In all data sets, radiographic scores were log-transformed (log(score+1)) to approximate a 
normal distribution. The residuals of the used models were normally distributed around the 
0-line in all cohorts, indicating a good fit of the models (see Supplementary Figure 1, 
available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/
10.1002/art.39018/abstract).
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In the cohorts in which multiple sets of radiographs were obtained over time (EAC, Umeå, 
and HCSC-RAC), a multivariate normal regression model for longitudinal data was used 
with radiographic scores as outcome (1,25,26). This method takes advantage of the within-
person correlation between repeated measurements; as such the radiographic progression 
rates were estimated more precisely in the cohorts with serial radiographs compared to data 
sets with one radiograph per patient (for a detailed description, see ref. 26). In the cohort in 
which a radiograph set was obtained at a single time point (NDB), the estimated yearly 
progression rate was calculated (total SHS/disease duration in years at time of radiograph) to 
make the estimates of the progression rates comparable to those in the other data sets. Linear 
regression analysis was used with estimated yearly progression as outcome variable. In both 
models used, the effect sizes obtained were back-transformed and indicated the fold rate of 
joint destruction per year per risk amino acid compared to the reference.
In all data sets, adjustments were made for age and sex. In the cohorts that included patients 
in periods with different treatment strategies (EAC, Umeå, and HCSC-RAC), analyses were 
also adjusted for the inclusion period as proxies for differences in treatment strategies.
The individual data sets studied were estimated to be insufficiently powered to find 
statistically significant associations when performing conditional analyses. Therefore, the 
effect sizes and standard errors of the results from the individual cohorts were combined in 
inverse-weighted variance meta-analyses with fixed effects to test the overall association. 
This was allowed because the effect sizes obtained for the individual data sets, though 
different methods were used to score joint destruction (SHS and Larsen), all represented the 
relative increase (without units) of progression in joint destruction per year. The meta-
analysis weights the results with a low standard error stronger than the results with a high 
standard error, preventing an overrepresentation of less precise data in the outcome. 
Subsequently, data sets with smaller 95% confidence intervals had a larger weight in the 
meta-analysis. P values less than 0.05 were considered significant. Statistical analysis was 
performed using SPSS version 20 and Stata 12.0.
RESULTS
Frequencies of variants
The allele frequencies of HLA–DRB1 SE and the amino acids at HLA–DRB1 position 11, 
HLA–B position 9, and HLA–DPB1 position 9 in the total population studied are presented 
in Figure 1. Of the 6 amino acids possible at HLA–DRB1 position 11, Val, Ser, and Leu 
were most prevalent in the total RA population (prevalence of 33.2%, 31.7%, and 14.0%, 
respectively). Within the ACPA-positive group of RA patients, Val was the most prevalent 
amino acid (41.6%), and within the ACPA-negative group, Ser was the most prevalent 
(43.7%). At HLA–B position 9, Tyr was the most prevalent and Asp the least prevalent 
amino acid (prevalence of 62.4% and 12.6%, respectively). At HLA–DPB1 position 9, Phe 
was the most common amino acid with a prevalence of 74.4%. For HLA–B and HLA–
DPB1, the frequencies of amino acids were similar for ACPA-positive and ACPA-negative 
RA.
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HLA–DRB1 SE alleles
First, the association between the HLA–DRB1 SE alleles and radiographic progression was 
studied. As expected, the SE alleles were associated with more severe radiographic 
progression (P = 6.41 × 10−7 in the fixed-effects meta-analysis of the 4 cohorts) (Figure 2). 
When SE and ACPAs were analyzed concomitantly, the significance of the SE alleles was 
lost (meta-analysis P = 0.20) and ACPA was still significant (meta-analysis P = 2.22 × 
10−16). The association between the SE alleles and radiographic progression was thus not 
independent of ACPAs, suggesting that ACPAs play a role in the causal path of the SE 
alleles and radiographic progression.
HLA–DRB1 position 11
Patients with the risk amino acids Val and Leu had a higher rate of joint damage 
progression; this reached statistical significance in 3 individual cohorts (EAC P = 4.94 × 
10−5, Umeå P = 0.032, and NDB P = 0.013) and in the meta-analysis (P = 5.11 × 10−7) 
(Figure 2). To illustrate, the raw radiographic data for RA patients included in the Leiden 
EAC are presented in Figure 3. In these patients, the presence of one Val or Leu amino acid 
was associated with a 1.033-fold rate of joint destruction per year compared to patients 
without these amino acids; this equals a 26% (1.033 to the power 7) higher rate of joint 
destruction over 7 years. To further illustrate the effects, RA patients with 1 and 2 Val or 
Leu amino acids, respectively, had SHS scores that were 10 and 16.5 points higher than 
patients without any Val or Leu amino acids (Figure 3). Conditioning on SE status revealed 
an independent association of position 11 with radiographic progression (meta-analysis P = 
0.022) (Figure 2). This indicates that Val or Leu on HLA–DRB1 position 11 was associated 
with radiographic progression independent of the HLA–DRB1 SE status.
In order to determine whether the effect of Val and Leu at position 11 on radiographic 
progression was independent of the effect of ACPAs on radiographic progression, analyses 
were also adjusted for ACPA status. Similar to the SE alleles, the effect of Val and Leu on 
radiographic progression was not independent of ACPA status (meta-analysis P = 0.12).
We next studied amino acid Ser at HLA–DRB1 position 11 in more detail, since this variant 
was reported to protect against RA (10). Analysis showed that Ser was associated with a 
lower rate of joint destruction (meta-analysis P = 5.99 × 10−3) (Figure 4A).
Because of the polymorphic nature of HLA–DRB1 and because predisposing as well as 
protective associations of variants encoded by the same position with radiographic 
progression were observed, we subsequently performed stratified analyses to distinguish 
between true-positive signals (i.e., a truly predisposing variant) and false-positive signals 
(i.e., seemingly predisposing but actually caused by the absence of protective variants). 
First, the association of Val and Leu was studied when comparing patient groups with S/S, 
S/N, and N/N, thus excluding patients with the protective amino acid Ser. Carrying Val and 
Leu was still associated with more radiographic progression (meta-analysis P = 0.010) 
(Figure 5A), and this association remained after additionally conditioning on SE status 
(meta-analysis P = 0.012) (Figure 5B), indicating a truly predisposing association for Val 
and Leu with radiographic progression. Furthermore, when performing stratified analysis to 
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evaluate the effect of Ser in patients not carrying the predisposing variants Val and Leu (thus 
comparing 3 groups of patients: P/P, P/N, and N/N) the protective effect of Ser was lost 
(meta-analysis P = 0.48) (Figure 4B). This might suggest that the protective effect of Ser 
observed in the total RA population was the consequence of the absence of the predisposing 
amino acids Val and Leu rather than a truly protective effect.
HLA–B position 9
Because risk factors for RA located outside the HLA–DRB1 region were also identified, we 
subsequently studied the association of 2 amino acids that are located elsewhere in the HLA 
region. First, the association between amino acid Asp at HLA–B position 9 and radiographic 
progression was assessed. No association was observed, neither in the individual cohorts nor 
in a meta-analysis (meta-analysis P = 0.43). Also, no tendency for association was observed 
(Figure 2) (Figure 3 illustrates the raw radiographic data for HLA–B position 9 in the Dutch 
RA patients).
HLA–DPB1 position 9
The other variant that is not located within the HLA–DRB1 region was HLA–DPB1. Amino 
acid Phe at position 9 in HLA–DPB1 was significantly associated with more severe 
radiographic progression (meta-analysis P = 0.024) (Figure 2) (Figure 3 illustrates raw 
radiographic data for RA patients in the EAC). However, after conditioning on SE status, no 
significance was obtained (meta-analysis P = 0.093) (Figure 2). Furthermore, when 
conditioning the effect of Phe for ACPA significance was lost (meta-analysis P = 0.27).
Predisposing variants within ACPA-negative RA
Recently, the amino acids Leu and Ser on HLA–DRB1 position 11 and Asp on B position 9 
were identified as risk factors for ACPA-negative RA (11). Associations between these 
amino acids and radiographic progression were also studied within the ACPA-negative 
subgroup, consisting of 657 patients with 1,877 radiograph sets. No significant results were 
obtained for Leu/Ser at HLA–DRB1 position 11 or Asp at HLA–B position 9 (meta-analysis 
P = 0.18 and P = 0.28, respectively). Also, the directionality of the effects was diverse 
(Figure 6) (see Supplementary Figure 2, available on the Arthritis & Rheumatology web site 
at http://onlinelibrary.wiley.com/doi/10.1002/art.39018/abstract).
DISCUSSION
This study was undertaken to investigate whether genetic variants at HLA–DRB1 position 
11, HLA–B position 9, and HLA–DPB1 position 9, which were recently identified as risk 
factors for RA, were also associated with radiographic progression in RA, and whether the 
associations were independent of HLA–DRB1 SE status and ACPA status. We observed that 
RA patients carrying the amino acids Val or Leu at HLA–DRB1 position 11 had more 
severe radiographic progression. Despite linkage between the variants at position 11 and the 
HLA–DRB1 SE alleles, the effect of Val and Leu was independent of the known SE effect. 
In addition, similar to the SE alleles, the effect of Val and Leu at HLA–DRB1 position 11 
was not independent of ACPA. Therefore, the findings of the present study validate the 
relevance of these amino acids at position 11 in HLA–DRB1.
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Identifying which variants in the HLA region are associated with the development or course 
of RA provides the opportunity to increase the understanding of the mechanisms underlying 
the progression of RA. The recent observation that the genetic variants that are associated 
with risk of RA development and those that are associated with risk of a progressive course 
of RA are largely different suggests that the processes driving disease development and 
disease severity are to a large extent dissimilar (1). However, a few genetic variants are risk 
factors for both RA development and RA severity, highlighting the importance of the 
pathway indicated by these risk factors throughout the disease. One such risk factor is the 
presence of the SE alleles encoded by HLA–DRB1 positions 70–74, which act via ACPAs 
on disease development and outcome. The findings of the present study demonstrate that 
Val and Leu at HLA–DRB1 position 11 are also associated with both the development and 
severity of RA as measured by radiographic progression.
The hope of the formulation of the SE hypothesis was that it would allow the identification 
of the auto-antigens of RA (6). However, thus far, arthritogenic peptides have not been 
found. Mouse studies have revealed that small changes in amino acids located within the 
antigen-presenting binding site may have large influences on the antigens that are presented 
(12,13). The amino acids at position 11 and position 13 are observed to be in very tight 
linkage disequilibrium (10); therefore, only the amino acids of position 11 were analyzed. 
Future studies will reveal whether taking the amino acids at position 11 and 13 into account 
will be helpful in identifying the pathogenic antigens that result in immune activation and 
autoantibody production, thereby stimulating disease development or progression.
Investigation of the HLA region is challenging due to high linkage disequilibrium. This is 
illustrated by the fact that 91.8% of all patients evaluated in the present study that had 0, 1, 
or 2 SE alleles also had, respectively, 0, 1, or 2 Val/Leu amino acids at HLA–DRB1 position 
11, implying that the observation of an additive value of position 11 was actually based on a 
relatively small proportion of patients. In addition, the association between SE and 
radiographic progression is strong, providing another reason why large data sets are required 
to determine whether other HLA variants have additional effects that are independent of the 
SE effect. Thus far, to the best of our knowledge, no studies have been published providing 
replication of the results regarding RA susceptibility published by Raychaudhuri et al in 
completely independent data sets (10). Also in this respect, the findings of the present study, 
though evaluating a different outcome, support the relevance of position 11 on HLA–DRB1.
In addition to linkage and power issues, the polymorphic nature of the HLA–DRB1 region 
in which the same position can encode for both predisposing and protective variants adds 
another level of complexity. To unravel these effects, adjusted multivariable analyses and 
stratified analyses can be done. The advantage of adjusting in multivariable analyses is that 
it is more powerful than subgroup analyses; however, this is at the cost of possible 
disturbing effects due to the assumptions underlying the model and eventual disturbances 
due to multicollinearity. In our view, in the present setting, stratified analyses yield the most 
conclusive results. We observed that Val and Leu at HLA–DRB1 position 11 were truly 
predisposing to more severe disease. In contrast, our data suggested that carrying the amino 
acid Ser at the same position was not protective. Although a protective effect was observed 
initially, in stratified analyses (excluding the effect of the absence of predisposing effects of 
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Val and Leu), Ser was not significantly associated with less severe radiographic progression. 
These data might suggest that Ser does not have a protective effect on the severity of 
radiographic progression in RA. However, it is also possible that the present study was 
insufficiently powered to detect a protective effect of Ser in the subgroup of patients studied. 
We cannot discriminate between these two possible explanations, and further studies are 
needed to determine the association of Ser with the severity of radiographic progression.
Raychaudhuri et al also defined 16 haplotypes, based on positions 11, 71, and 74 in HLA–
DRB1 (10). We did not perform haplotype analyses, since in our view stratification is 
needed to distinguish predisposing or protective haplotypes from the absence of protective 
and predisposing haplotypes, respectively, and then subgroups became too small.
Within the field of RA susceptibility, it has been notable that Ser has been reported to be 
protective against ACPA-positive RA but predisposing to ACPA-negative RA (10,11). 
Because of this finding, we also evaluated the association of Ser with progression in the 
ACPA-negative subgroup. The presence of Ser in these patients was not associated with the 
severity of radiographic progression.
We could not identify an association between Asp at HLA–B9 and radiographic progression. 
This position, which is highly correlated with HLA–B*08, is part of the conserved ancestral 
A1–B8–DRB1*03 (8.1) haplotype and has been associated with susceptibility to ACPA-
negative disease (8,9). In contrast to the undisputed association of DRB1*03 or this 
haplotype with susceptibility to ACPA-negative RA, we did not detect an association with 
the severity of the disease in RA or in ACPA-negative RA.
The presence of Phe at HLA–DPB1 position 9 was associated with the severity of 
radiographic progression, but significance was lost (P = 0.093) when conditioning for the 
HLA–DRB1 SE status. This might suggest that Phe at HLA–DPB1 is not associated with 
radiographic progression independent of the association between SE status and radiographic 
progression. Notably, the directionality of the effect of Phe at HLA–DPB1 was similar in all 
cohorts, with more severe progression in the patients carrying Phe. Although the linkage 
between this position with the HLA–DRB1 SE alleles is less than for HLA–DRB1 position 
11 with SE (in our study 32.7% of the patients who had 0, 1, or 2 SE alleles also had, 
respectively, 0, 1, or 2 Phe amino acids at HLA–DPB1 position 9), it is possible that our 
data were insufficiently powered to find an independent association of Phe with 
radiographic progression. The present data do not allow making definite conclusions 
regarding HLA–DPB1 and radiographic progression; though if an effect is present, this 
effect seems to act in the path of ACPAs, similar to HLA–DRB1.
In order to get some indication of the variance in joint destruction explained by the genetic 
factors studied, the interindividual variance in joint destruction in the Leiden RA patients at 
year 7 was evaluated. The SE alleles explained 4.2% of the variance in joint destruction and 
the combination of SE alleles, HLA–DRB1 position 11, HLA–DPB1 position 9, and HLA–
B position 9 explained 4.5%. This is lower than the variance in the risk of ACPA-positive 
RA explained by a combination of HLA–DRB1 positions 71, 74, and 11, HLA–DPB1 
position 9, and HLA–B position 9, which was reported to be 12.7% (10).
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To conclude, Val and Leu at position 11 in the HLA–DRB1 locus were recently identified as 
additional susceptibility factors for ACPA-positive RA. We observed that these amino acids 
were also associated with a more severe disease course, an effect that was not independent 
of ACPA status. Further 3-dimensional modeling studies or binding assays, such as 
described previously by Scally et al (27) are needed to determine whether the present 
findings result in novel insights in the consequences of the HLA–DRB1 motif on antigen 
presentation and its function as an immune response gene.
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Figure 1. 
Frequencies of HLA–DRB1 shared epitope (SE) alleles and the amino acids at HLA–DRB1 
position 11, HLA–B position 9, and HLA–DPB1 position 9. Frequencies are expressed as 
the percentage of a total of 3,756 alleles/amino acids. Of the 1,878 patients, 69.0% were 
positive for the HLA–DRB1 SE (at least 1 SE allele), 71.2% were positive for Val/Leu at 
HLA–DRB1 position 11 (at least 1 Val or Leu amino acid), 23.8% were positive for Asp at 
HLA–B position 9 (at least 1 Asp), and 93.0% were positive for Phe at HLA–DPB1 position 
9 (at least 1 Phe). ACPA = anti–citrullinated protein antibody.
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Figure 2. 
Associations of amino acids at HLA–DRB1, HLA–B, and HLA–DPB1 that are known to 
predispose to rheumatoid arthritis (RA) development with radiographic progression in RA. 
The yearly radiographic progression rates per risk amino acid in each individual cohort are 
shown. P values are from the fixed-effects meta-analyses evaluating the 4 cohorts, which 
consisted of a total of 1,878 patients and 4,911 sets of radiographs. Risk amino acids were 
defined according to the findings of Raychaudhuri et al (10). For the DRB1 shared epitope 
(SE), I2 = 22.9%, P = 0.27, fixed-effects P = 6.41 × 10−7, and random-effects P = 2.01 × 
10−4. For Val/Leu at DRB1 position 11, I2 = 23.0%, P = 0.27, fixed-effects P = 5.11 × 10−7, 
and random-effects P = 2.19 × 10−4. For Val/Leu at DRB1 position 11 adjusted for SE 
status, I2 = 37.3%, P = 0.19, fixed-effects P = 0.022, and random-effects P = 0.066. For Asp 
at B position 9, I2 = 0.0%, P = 0.59, fixed-effects P = 0.43, and random-effects P = 0.43. 
For Phe at DPB1 position 9, I2 = 0.0%, P = 0.85, fixed-effects P = 0.024, and random-
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effects P = 0.024. For Phe at DPB1 position 9 adjusted for SE status, I2 = 0.0%, P = 0.90, 
fixed-effects P = 0.093, and random-effects P = 0.093. EAC = Early Arthritis Clinic; HCSC-
RAC = Hospital Clinico San Carlos–Rheumatoid Arthritis Cohort; NDB = National Data 
Bank for Rheumatic Diseases; ES = effect size; 95% CI = 95% confidence interval.
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Figure 3. 
Radiographic progression in rheumatoid arthritis patients in the Leiden Early Arthritis Clinic 
cohort per number of risk alleles or amino acids at HLA–DRB1, HLA–B, and HLA–DPB1. 
The median raw and unmodeled Sharp/van der Heijde scores (SHS) during 7 years of 
followup of 594 RA patients are shown. The P values obtained by multivariate normal 
regression analyses comparing the genotypes in relation to radiographic progression were P 
= 5.33 × 10−5 for the DRB1 shared epitope (SE) alleles, P = 4.94 × 10−5 for Val/Leu at 
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DRB1 position 11, P = 0.044 for Ser at DRB1 position 11, P = 0.62 for Asp at HLA–B 
position 9, and P = 0.036 for Phe at DPB1 position 9.
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Figure 4. 
Association of Ser at HLA–DRB1 position 11 with radiographic progression of rheumatoid 
arthritis in the total population and in the subgroup of patients who did not carry any 
predisposing Val or Leu amino acids. A, Yearly radiographic progression rates per Ser 
amino acid at HLA–DRB1 in the total population. Data are shown for each individual cohort 
and for the fixed-effects meta-analyses evaluating the 4 cohorts, consisting of a total of 
1,878 patients and 4,911 sets of radiographs. I2 = 0.0%, P = 0.40, fixed-effects P = 5.99 × 
10−3, and random-effects P = 5.99 × 10−3. B, Yearly radiographic progression rates per Ser 
amino acid at HLA–DRB1 in the patients who did not carry any predisposing Val or Leu 
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amino acids. To determine whether the observed association of Ser with radiographic 
progression was truly protective and not due to the concomitant absence of the predisposing 
amino acids Val and Leu, analyses were performed within the subgroup of patients not 
carrying Val and Leu (thus, patients with 2 copies of Ser, patients with 1 Ser and 1 neutral 
amino acid, and patients with 2 neutral amino acids were compared). Data are shown for 
each individual cohort and for the fixed-effects meta-analyses evaluating the 4 cohorts, 
consisting of a total of 541 patients and 1,477 sets of radiographs. I2 = 9.5%, P = 0.35, 
fixed-effects P = 0.48, and random-effects P = 0.56. See Figure 2 for definitions.
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Figure 5. 
Association of Val and Leu at HLA–DRB1 position 11 with radiographic progression in the 
subgroup of rheumatoid arthritis patients who did not carry any Ser at position 11 and with 
additional adjustment for shared epitope (SE) status. A, Yearly radiographic progression 
rates per Val or Leu amino acid at HLA–DRB1 position 11 in patients who did not carry any 
Ser at position 11. These analyses were performed to determine whether the observed 
association of Val and Leu with radiographic progression was truly predisposing and not due 
to the concomitant absence of Ser (thus, patients carrying 2 copies of Val or Leu, patients 
with 1 Val or Leu and 1 neutral amino acid, and patients with 2 neutral amino acids were 
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compared). Data are shown for each individual cohort and for the fixed-effects meta-
analyses evaluating a total of 781 patients and 1,747 sets of radiographs. I2 = 0.0%, P = 
0.92, fixed-effects P = 0.010, and random-effects P = 0.010. B, Yearly radiographic 
progression rates per Val or Leu amino acid at HLA–DRB1 position 11 in patients who did 
not carry any Ser at position 11, adjusted for SE status. I2 = 0.0%, P = 0.90, fixed-effects P 
= 0.012, and random-effects P = 0.012. See Figure 2 for definitions.
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Figure 6. 
Association of Leu and Ser at HLA–DRB1 position 11 and Asp at HLA–B position 9 with 
radiographic progression in anti–citrullinated protein antibody (ACPA)–negative RA. Data 
are shown for each individual cohort and for the fixed-effects meta-analyses evaluating the 4 
cohorts, consisting of a total of 657 patients and 1,877 sets of radiographs. Risk amino acids 
were defined according to the findings of Han et al (11). A, Yearly radiographic progression 
rates per risk amino acid Leu or Ser at HLA–DRB1 position 11 in ACPA-negative patients. 
I2 = 60.8%, P = 0.054, fixed-effects P = 0.18, and random-effects P = 0.59. B, Yearly 
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radiographic progression rates per risk amino acid Asp at HLA–B position 9 in ACPA-
negative patients. I2 = 0.0%, P = 0.56, fixed-effects P = 0.28, random-effects P = 0.28. See 
Figure 2 for other definitions.
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